Fluence Partners With Dutch Research Organization Innexo BV to Support Better Access to Cannabis Research
18.5.2023 16:00:00 EEST | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today an extension of its research partnership with Dutch organization Innexo BV (Innexo), a specialty agricultural contract research organization (CRO) that focuses on molecular farming and medicinal plants.
Innexo is leveraging Fluence’s VYPR Broad R4 LED solution to support its new Acceleration Platform for Innovation (API) program. API empowers innovative, small-scale companies adjacent to the cannabis industry to perform research in medical cannabis cultivation. API’s first round of participants, which include companies like biostimulant and fertilizer producers, will conduct research trials that focus on plant health, strength and resilience beneath Fluence LEDs.
“Fluence is the natural choice for a lighting provider to support API because we share a common vision to make research accessible and drive technological innovations that unlock the future of medical cannabis cultivation,” said Dominique van Gruisen, managing director of Innexo. “Fluence’s science-backed product development and in-house team of horticultural experts is unique among lighting providers. The insight and guidance API participants will receive from subject matter experts at Innexo and Fluence will accelerate their ability to build intellectual property through these research trials.”
Innexo and Fluence’s research collaboration started in October 2022. The companies, which are both recognized as innovators in cannabis research, first came together to investigate the effects of intra-canopy lighting versus top lighting applications in medical cannabis plants.
“The milestones we’re experiencing in the legalization of cannabis in Europe, such as cannabis clubs for cultivation in Germany and the Dutch coffee shop tender, demonstrate significant opportunities and demand for the expansion of cannabis cultivation knowledge,” said Timo Bongartz, general manager of Europe, Middle East and Africa at Fluence. “An increase in research questions has naturally accompanied the expansion of the legal market but is not always backed by the proper resources for exploration. Partnering with a cannabis research trailblazer like Dominique provides the opportunity to facilitate important access to tools that further innovation at Innexo BV.”
Fluence will continue its commitment to furthering cannabis research to help the world grow smarter at GreenTech Amsterdam 2023, one of the largest cannabis industry events in the world. Fluence’s GreenTech booth will host a series of research sessions, featuring Dominique van Gruisen and Fluence experts Dr. David Hawley, principal scientist, and Sebastian Olschowski, research project manager for EMEA.
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
About Innexo BV
Innexo BV is a specialty agricultural contract research organization (CRO) based in the Netherlands. The focus and expertise of the company are in medicinal plants, such as cannabis and molecular farming in general. Innexo BV is part of the Botany Group of companies. To learn more about Innexo BV, visit botanygroup.nl/en/innexo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005301/en/
Contact information
For EMEA,
Silvia Nagyova
silvia.nagyova@fluence-led.com
+49 160 93335045
For North America,
Callie Neatherlin
callie@redfancommunications.com
512-439-9720
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UAE Commits $49bn to Local Manufacturers7.5.2026 17:00:00 EEST | Press release
The United Arab Emirates (UAE) pledged $49 billion in industrial procurement opportunities on Monday and announced plans to localize more than 5,000 products as the Gulf state doubled down on its industrial sovereignty agenda. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507855698/en/ UAE commits $49bn to local manufacturers (Photo: AETOSWire) Dr. Sultan Al Jaber, UAE Minister of Industry and Advanced Technology, made the announcement at the opening of the fifth edition of Make it in the Emirates, which follows a period that has tested the region. “History remembers the challenges nations face. But it also remembers how nations respond to them and what they build next,” he said. TA’ZIZ announced $40.5 billion worth of agreements aimed at expanding UAE chemical production capacity. The opportunities include offtakes and $2 billion of financing for the UAE’s first world-scale methanol plant. A $270 million National Indust
Andersen Consulting Strengthens Organizational Transformation Capabilities with Afiniti7.5.2026 16:30:00 EEST | Press release
Andersen Consulting announces a Collaboration Agreement with Afiniti, a global business transformation consultancy headquartered in the United Kingdom that helps organizations deliver and sustain complex change programs. Founded in 2003, Afiniti is a global business change consultancy based in the UK and U.S., supporting clients through complex transformation across people, process, systems, and data, and bringing change to life through creative consulting services. The firm primarily serves highly regulated, safety-driven, and asset-intensive organizations with large, geographically dispersed workforces across sectors including energy, utilities, life sciences, transport, and construction. Afiniti works with well-known brands to deliver end-to-end expertise across organizational, digital and AI, cultural, and operating model transformation, particularly in complex scenarios such as mergers and acquisitions, large-scale technology adoption, and underperforming change programs that have
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 16:07:00 EEST | Press release
Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™, and API Media operations into a new stand-alone public company, which is proposed to be named “API Media”. The Company has reserved the ticker symbol “ADIO” for the proposed spin-out entity and currently intends that API Media will be listed on NASDAQ following completion of the proposed transactions, which remain subject to approval by the Company’s board of directors, definitive agreement, and satisfaction of closing conditions, as well as any regulatory approvals that may be required in connection therewith. The Company has engaged Houlihan Lokey as its financial advisor and Paul Hastings LLP as its lega
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 15:50:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium, being held May 7–9, 2026, in Athens, Greece. As previously reported, the TRuE-AD4 study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on Opzelura versus vehicle cream achieving EASI75 (≥75% improvement in Eczema Area and Severity Index score from baseline) and, separately, IGA-TS (Investigator's Global Assessment Treatment Success, defined as an IGA score of 0 [clear] or 1 [almost clear] with at least a two-point improvement from baseline).1 Patients who
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom